Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;87:189-194

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ventura, C.
Right arrow Articles by Maioli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ventura, C.
Right arrow Articles by Maioli, M.
Related Collections
Right arrow Gene expression
Right arrow Myogenesis
Right arrow Cardiac development
(Circulation Research. 2000;87:189.)
© 2000 American Heart Association, Inc.


Molecular Medicine

Opioid Peptide Gene Expression Primes Cardiogenesis in Embryonal Pluripotent Stem Cells

Carlo Ventura, Margherita Maioli

From the Department of Biomedical Sciences, Division of Biochemistry, Laboratory of Cardiovascular Research, University of Sassari, Sassari, Italy, and National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy.

Correspondence to Carlo Ventura, MD, PhD, Department of Biomedical Sciences, Division of Biochemistry, University of Sassari, Viale San Pietro 43/B, 07100 Sassari, Italy. E-mail chim_med{at}ssmain.uniss.it


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Zinc finger–containing transcription factor GATA-4 and homeodomain Nkx-2.5 govern crucial developmental fates and have been found to promote cardiogenesis in embryonic cells exposed to the differentiating agent DMSO. Nevertheless, intracellular activators of these transcription factors are largely unknown. In this study, pluripotent P19 cells expressed the prodynorphin gene, an opioid gene encoding for the dynorphin family of opioid peptides. P19 cells were also able to synthesize and secrete dynorphin B, a biologically active end product of the prodynorphin gene. DMSO-primed GATA-4 and Nkx-2.5 gene expression was preceded by a marked increase in prodynorphin gene expression and dynorphin B synthesis and secretion. The DMSO effect occurred at the transcriptional level. In the absence of DMSO, dynorphin B triggered GATA-4 and Nkx-2.5 gene expression and led to the appearance of both {alpha}-myosin heavy chain and myosin light chain-2V transcripts, two markers of cardiac differentiation. Moreover, dynorphin B–exposed cells were positively stained in the presence of MF 20, a mouse monoclonal antibody raised against the {alpha}-myosin heavy chain. Opioid receptor antagonism and inhibition of opioid gene expression by a prodynorphin antisense phosphorothioate oligonucleotide blocked DMSO-induced cardiogenesis, suggesting an autocrine role of an opioid gene in developmental decisions.


Key Words: opioid gene expression • myocardial development • transcription factors • stem cells


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Heart development is one of the first morphogenetic events occurring in the embryo and is a complex process involving cell proliferation and differentiation as well as tissue organization into a specific architecture. The analysis of myocardial differentiation lies in determining how a small number of tissue-restricted transcription factors can establish a complex pattern of developmental and tissue-specific gene expression. It is now recognized that Nkx-2.5, a vertebrate homologue of the Drosophila tinman gene,1 is essential for the specification of myocardial progenitors in the fly2 and is also involved in heart looping in mice.3 Recently, mutations in the transcription factor Nkx-2.5 have been shown to cause congenital heart diseases, even in humans,4 and impair normal heart architecture by affecting diverse cardiac developmental pathways in a wide population of cardiopathic patients.5 GATA-4, a member of the zinc finger–containing GATA factors,6 also plays a key role in cardiac muscle development and has been found to govern the expression of several cardiac-specific genes, including {alpha}-myosin heavy chain (MHC), cardiac troponin C, and atrial natriuretic peptide.6 The availability of pluripotent embryonal stem (ES) cells now provides a valuable tool for the molecular dissection of developmental events. P19 is a line of pluripotent murine ES cells that can be differentiated into multiple cell types by cellular aggregation in the presence of differentiating agents and emulates the molecular and morphological events occurring during early embryonic development.7 P19 cells treated with retinoic acid differentiate into various neuroectodermal derivatives, whereas cells aggregated in the presence of DMSO differentiate into cardiac and skeletal muscle along with other mesodermal and endodermal cell types.7 The resulting cardiomyocytes have been found to be embryonic in nature and express both GATA-4 and Nkx-2.5 genes.8 In P19 cells, inhibition of GATA-4 expression blocked DMSO-induced cardiogenesis,9 whereas transfection of the Nkx-2.5 gene led to the appearance of a myocardial lineage in the absence of DMSO.8 These findings indicate that the establishment of a cardiac phenotype proceeds with similar molecular patterning in P19 cells and in the in vivo environment and suggest that these cells should be considered as an in vitro model recapitulating the molecular plight that is impacting the process of cardiogenesis in the developing embryo. The identification of intracellular growth regulators capable of priming cardiogenesis is now a crucial issue. Increasing experimental evidence indicates that the myocardial cell may act as a source for peptides, playing a crucial role in signal transduction mechanisms. We have shown that cardiac myocytes express the prodynorphin gene and are able to synthesize and secrete dynorphin B,10 a natural {kappa}-opioid receptor agonist. Stimulation of these receptors modified both cytosolic Ca2+ and pH homeostasis and remarkably affected myocardial contractility.11 12 It is now established that opioid peptides can also act as growth regulators in a wide variety of normal and malignant tissues.13 14 15 In our previous investigations, prodynorphin gene and dynorphin B expression were enhanced in myocytes isolated from BIO 14.6 Syrian hamsters,16 an experimental model of hereditary cardiomyopathy exhibiting remarkable changes in myocyte architecture, growth, and differentiation. In this model, the overexpression of the prodynorphin gene was related to both the activation of nuclear embedded isozymes of protein kinase C (PKC) and cytosolic Ca2+ overload,16 17 suggesting the recruitment of crucial signaling pathways. Interestingly, in cardiomyopathic myocytes, secreted dynorphin B elicited a tonic feed-forward stimulation of its coding gene.18 Moreover, recently uncovered nuclear opioid receptors were found to be coupled to the activation of both nuclear PKC activity and prodynorphin gene transcription.19 These findings suggest that an opioid gene may play an autocrine and intracrine role in the regulation of myocardial homeostasis.

In the present study, we used P19 ES cells to examine prodynorphin gene transcription and dynorphin B expression throughout different stages of DMSO-induced cardiac differentiation. In this in vitro model, we also aimed to elucidate whether the expression of a cardiogenic program may be triggered by the exposure of P19 cells to dynorphin B in the absence of DMSO. A potential role of the prodynorphin gene and endogenous dynorphin B in cardiogenesis was explored.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Differentiation
P19 cells (European Collection of Cell Cultures) were grown and differentiated as previously described.7 Briefly, 105 cells/mL were grown in suspension in 60-mm bacteriological Petri dishes (Falcon) in medium containing 1% DMSO or the indicated concentrations of dynorphin B. At day 2, the medium was changed to fresh DMSO-containing medium, and at day 4 the aggregates were plated into tissue culture–grade dishes (Falcon) and maintained without any drug. Days of differentiation were numbered consecutively after the first day of aggregation.

Reverse Transcription–Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted at the indicated time and reverse transcribed. The resulting cDNA was then amplified according to the reaction conditions previously reported.20 Using 35 PCR cycles, the products of the investigated genes were all within the linear phase of the reaction. Specific primers for MHC, myosin light chain-2V (MLC), GATA-4, Nkx-2.5, and GAPDH are described elsewhere (see expanded Materials and Methods online, available at http://www.circresaha.org). Specific primer pairs against mouse prodynorphin gene were 5'-CTGCTGACCGGATGAATGATGAA-3' and 5'-GCAGCGGAACAAGCACAAGAGGAT-3'. PCR conditions were 94°C for 30 seconds, 59°C for 30 seconds, and 72°C for 1 minute.

Analysis of Prodynorphin Gene Expression
Prodynorphin mRNA was also assessed by solution hybridization RNase protection.13 20 Briefly, a 424-bp fragment of the main exon of mouse genomic prodynorphin clone was inserted into pCRII-TOPO (Invitrogen). Transcription of the plasmid linearized with ApaI generated a sense strand of prodynorphin mRNA used to construct a standard curve of prodynorphin mRNA, whereas transcription of the plasmid linearized with BamHI in the presence of [32P]CTP (800 Ci/mmol) gave an antisense strand used to hybridize cellular prodynorphin mRNA.

Nuclear runoff transcription assay was performed in isolated nuclei, as described.16 Nuclear RNA was subjected to RNase protection assay. 32P-labeled RNA was hybridized for 12 hours at 55°C with unlabeled antisense prodynorphin mRNA synthesized, as described above. 32P-labeled nuclear RNA was also hybridized with unlabeled antisense cyclophilin mRNA, used as a constant mRNA for control. Immunoreactive dynorphin B was measured by a previously described radioimmunoassay procedure.10 16

Transfections
Undifferentiated P19 cells were transfected with 200 nmol/L prodynorphin antisense phosphorothioate oligonucleotide or 200 nmol/L scrambled phosphorothioate oligomer (negative control) (Sequitur Inc) with the aid of cationic lipids (Oligofectins) provided by the manufacturer. Transfection was carried out for 4 hours at 37°C in a serum-free medium. Cells were then replaced in a serum-containing medium and, after a 24-hour period, were exposed to 1% DMSO. The transfection procedure was repeated at 48-hour intervals. A fluorescein-labeled derivative of the antisense oligonucleotide was used to determine transfection efficiency. Fluorescence microscopy performed at defined times after transfection revealed that >=90% of identifiable nuclei had taken up the fluorescent oligonucleotide and that nuclear staining persisted for the duration of the experiment (not shown). After 4 days of DMSO treatment, cells were fixed with 4% paraformaldehyde and MHC was identified by the MF 20 mouse antimyosin monoclonal antibody.21

An expanded Materials and Methods section is available online at http://www.circresaha.org.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Nkx-2.5 and GATA-4 gene expression was induced after 2 or 4 days of treatment with 1% DMSO, respectively (Figure 1Down). According to previous studies,8 9 basal mRNA expression was not detectable in P19 cells cultured in the absence of the differentiator. DMSO-mediated induction of GATA-4 and Nkx-2.5 preceded the expression of MHC and MLC genes, two cardiac muscle genes (Figure 1Down).



View larger version (38K):
[in this window]
[in a new window]
 
Figure 1. Effects of DMSO on the expression of targeted cardiogenic genes in P19 cells. At the indicated time points, total RNA was extracted and processed for RT-PCR analysis. Each row shows ethidium bromide–stained agarose gels of the PCR amplification of the indicated transcripts.

In this study, we examined whether the increase in GATA-4 and Nkx-2.5 gene expression elicited by DMSO may be associated with the expression of an endogenous growth regulator in the early phase of the cardiac commitment of P19 cells. Figure 2Down shows that the prodynorphin gene was expressed under basal conditions in cells cultured without DMSO. RT-PCR suggested a substantial increase in prodynorphin mRNA after cell exposure to DMSO (Figure 2ADown). Such an effect was additionally confirmed by RNase protection experiments revealing that prodynorphin gene expression was already enhanced after 2 days in the presence of DMSO and reached a maximum after 4 days of treatment. In vitro runoff assays performed in nuclei isolated from P19 cells indicated that the DMSO effect occurred at the transcriptional level (Figure 2CDown).



View larger version (49K):
[in this window]
[in a new window]
 
Figure 2. DMSO triggers prodynorphin gene and dynorphin B expression in P19 cells. A, RT-PCR analysis of prodynorphin (prodyn) mRNA. B, RNase protection analysis of prodynorphin mRNA expression. Upper part of the panel shows representative autoradiograms of prodynorphin mRNA. Averaged values of prodynorphin mRNA expression (mean±SE; n=6) are reported in the lower part of the panel. *Significantly different from untreated controls (-). C, Nuclear runoff assay. a, Transcription of the prodynorphin gene. b, Cyclophilin mRNA. D, Immunoreactive dynorphin B (ir-dyn B). Gray bars indicate ir-dyn B in cells; and white bars, ir-dyn B in the medium. Values are mean±SE (n=6). §Value of white bar is significantly different from that of the gray bar; *Significantly different from untreated controls (-). An expanded version of the legend for Figure 2Up is available online at http://www.circresaha.org.

Consistent amounts of dynorphin B were detected in P19 cells and their incubation media (Figure 2DUp). Confirming our previous observations in myocardial cells,10 16 the intracellular levels of dynorphin B were significantly lower than the levels detected in the incubation medium, suggesting that in the P19 cell prodynorphin-derived peptides may be constitutively released soon after synthesis. The levels of both intracellular and secreted dynorphin B were significantly increased in DMSO-treated P19 cells compared with unexposed cells. The rise in dynorphin B expression was already evident after 2 days of treatment and peaked after 4 days of exposure (FigureUp 2D).

The finding that DMSO-triggered induction of cardiogenic genes was preceded by the activation of prodynorphin gene and dynorphin B expression suggests that an opioid gene may be a suitable candidate for the initiation of a cardiac program of differentiation. In the absence of DMSO, 1 µmol/L dynorphin B was able to induce the expression of Nkx-2.5 and GATA-4 genes after 1 or 2 days of treatment, respectively (Figure 3Down). Exposure to dynorphin B also enhanced MHC and MLC gene expression (FigureUp 3). The dose-response curve of the effect of dynorphin B on Nkx-2.5 and GATA-4 mRNA expression revealed that the opioid peptide was effective at a concentration as low as 10-8 mol/L (FigureUp 3). Figure 3Down shows that the opioid effect was specific in nature, because it was abolished by Mr-1452, a selective {kappa}-opioid receptor antagonist.19 MHC expression was additionally assessed in immunofluorescence studies with the aid of the mouse MF 20 monoclonal antibody. Whereas MF 20–positive cells were not detectable in the absence of both DMSO and dynorphin B (Figure 4ADown), MF 20 labeling was clearly observed in DMSO-treated cells (Figure 4BDown). Positive staining was also observed in P19 cells exposed to dynorphin B in the absence of DMSO (Figure 4CDown). The pattern of MF 20 staining in dynorphin B–treated cells was superimposable to that observed in cells exposed to DMSO, providing additional evidence for the involvement of dynorphin B in the activation of a cardiogenic program.



View larger version (60K):
[in this window]
[in a new window]
 
Figure 3. Effect of dynorphin B on the expression of a distinct cardiogenic program. P19 cells cultured without DMSO were treated in the absence or presence of dynorphin B. Total RNA was extracted and processed for RT-PCR analysis of the indicated transcripts. Ethidium bromide–stained gels represent the time course (top) or the dose response (bottom) of the effect of dynorphin B on targeted gene expression. Mr indicates cells cultured in the presence of 1 µmol/L dynorphin B and 1 µmol/L Mr-1452.



View larger version (49K):
[in this window]
[in a new window]
 
Figure 4. Dynorphin B induces cardiomyogenesis in P19 cells. P19 cells were aggregated for 4 days in the absence of both DMSO and dynorphin B (A), in the presence of 1% DMSO (B), or in the presence of 1 µmol/L dynorphin B (C) and stained on day 5 with MF 20, an anti-MHC monoclonal antibody. Bar=40 µm.

The cardiogenic effect of an exogenously administered opioid agonist prompted us to investigate whether an intrinsically produced opioid peptide may elicit cardiogenesis through an autocrine mechanism. For this purpose, cell aggregation with DMSO, a treatment enhancing the synthesis and secretion of dynorphin B, was performed in the presence of an opioid receptor antagonist. Figure 5Down shows that Mr-1452 downregulated DMSO-induced GATA-4 and Nkx-2.5 mRNA expression as well as DMSO-elicited activation of MHC and MLC genes. Specificity of the antagonistic effect of Mr-1452 was inferred by the finding that the inactive enantiomer Mr-1453 failed to abolish the DMSO action (Figure 5Down). We next assessed MHC expression in P19 cells transfected with a prodynorphin antisense phosphorothioate oligonucleotide. In cells primed for 4 days with 1% DMSO, transfection resulted in an 80% to 90% decrease in both intracellular and secreted dynorphin B compared with nontransfected DMSO-treated cells (Figure 6Down). The immunofluorescence analysis of MF 20 staining revealed that P19 prodynorphin antisense transfectants failed to develop in MHC-positive cells in response to DMSO (Figure 7Down). The treatment of P19 cells with Mr-1452 was also able to prevent the appearance of MF 20 staining in DMSO-exposed cells (Figure 7Down).



View larger version (38K):
[in this window]
[in a new window]
 
Figure 5. Effect of a specific opioid receptor antagonist on DMSO-induced cardiogenic program. P19 cells were exposed for 4 days to 1% DMSO in the absence or presence of 1 µmol/L Mr-1452 (Mr) or 1 µmol/L Mr-1453 (*Mr). Total RNA was then extracted and processed for RT-PCR analysis. Each row shows ethidium bromide–stained gels relating to the PCR amplification of the indicated transcripts.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 6. Downregulation of dynorphin B expression by a prodynorphin antisense phosphorothioate oligonucleotide. Effect of 4-day treatment with 1% DMSO was assessed in cells transfected with a prodynorphin antisense oligonucleotide (T) or scrambled oligomer (T*). NT indicates nontransfected cells; gray bar, immunoreactive dynorphin B (ir-dyn B) in cells; and white bar, ir-dyn B in the medium. Values are mean±SE (n=6). §Value of the white bar is significantly different from that of the gray bar. In the absence or presence of DMSO, ir-dyn B did not differ significantly among T* and NT groups.



View larger version (74K):
[in this window]
[in a new window]
 
Figure 7. Opioid receptor antagonism and transfection with a prodynorphin antisense oligomer prevent MHC expression. P19 cells were aggregated for 4 days in the absence (A) or presence (B) of 1% DMSO. C, Cells were cultured for 4 days with 1% DMSO in the presence of 1 µmol/L Mr-1452. D, P19 prodynorphin antisense transfectants were exposed for 4 days to 1% DMSO. E, P19 cells transfected with a scrambled oligomer were exposed for 4 days to 1% DMSO. Cells were stained on day 5 with MF 20. Bar=40 µm.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
Concerted activation of regulatory genes plays a fundamental role in determining the temporal and spatial patterns of embryonic development. Lineage-restricted transcription factors that regulate tissue-specific genes are especially important for tissue differentiation. Although the cardiac homeobox gene Csx/Nkx-2.5 and zinc finger–containing GATA-4 have been found to be essential for normal heart development, little is known about the molecular mechanism underlying their activation. Pluripotent P19 cells provide the opportunity of identifying intrinsic primers that may mimic the capability of DMSO to trigger the expression of genes involved in cardiogenic decision. The possibility that the activation of an endorphinergic system may act as an endogenous primer in the induction of cardiogenic genes is supported by the present observation that P19 cells express the prodynorphin gene and that DMSO-primed Nkx-2.5 and GATA-4 gene expression was preceded by a marked increase in expression of both prodynorphin gene and dynorphin B. Consistent with the role of the prodynorphin gene in specifying the cardiac lineage is the finding that the exposure of P19 cells to dynorphin B triggered the expression of both Nkx-2.5 and GATA-4 as well as the activation of cardiac-specific genes. A cardiogenic role of the prodynorphin gene is also supported by the finding that dynorphin B–treated cells were positively stained with MF 20, a specific anti-MHC antibody. In the present study, MF 20 staining was clearly evident after treatment for 4 days in the presence of DMSO or dynorphin B. This observation excludes the possibility that skeletal muscle cells may contribute to MHC expression, because in P19 cells, skeletal muscle does not appear until after 9 to 10 days of aggregation with DMSO.7 8 Additional evidence correlating the immunofluorescence results to the onset of a cardiac phenotype is provided by the observation that MF 20 staining was associated with the appearance of MLC transcript, a cardiac marker for ventricular chamber specification.6 The present finding that dynorphin B was synthesized and secreted from DMSO-treated P19 cells and that a specific {kappa}-opioid receptor antagonist suppressed the DMSO effect on cardiogenic and cardiac-specific genes prompts the hypothesis that cardiogenesis may be controlled by an opioid gene–related autocrine environment. Such a hypothesis is substantiated by the observation that both antisense-mediated downregulation of the prodynorphin gene and opioid receptor antagonism counteracted MHC expression.

Previous studies22 23 have established that both Nkx-2.5 and GATA-4 can be induced in mesoderm-originated precardiac cells by endoderm-derived signals comprising several members of bone morphogenetic proteins (BMPs) belonging to the transforming growth factor-ß superfamily. It is now evident that both BMP receptors and DMSO convey differentiating stimuli to the nuclear transcriptional machinery through common signal transduction pathways that involve the activation of mitogen-activated protein kinases (MAPKs).24 25 DMSO also elicits intracellular Ca2+ overload and phosphoinositide turnover, thereby increasing the cellular availability of diacylglycerol and the activity of PKC isozymes.26 27 Interestingly, opioid receptor stimulation is coupled to the activation of both PKC-16 28 29 and MAPK-mediated pathways30 and has also been shown to affect phosphoinositide turnover,12 31 promoting the release of Ca2+ from an intracellular storage site.10 11 12 18 In addition, an upstream initiator-like sequence in the promoter of the prodynorphin gene has been shown to be recognized by a DNA-binding protein acting as a tyrosine kinase substrate.32 Hence, opioid-related signaling shares crucial developmental pathways with both BMP- and DMSO-activated cascades. Opioid peptides have also been shown to be nuclear proteins responsive to growth arrest and differentiation signals.33 In this regard, the opioid peptide precursor preprodynorphin has been found to display structure similarity with the helix-loop-helix motif of multiple DNA-binding proteins and to exhibit cysteine-rich regions characteristic of zinc-finger domains.34 Moreover, dynorphin B proved to be a specific ligand of nuclear opioid receptors in myocardial cells.19 These receptors were overexpressed in nuclei of myocytes isolated from Syrian cardiomyopathic hamsters and coupled to nuclear PKC activation and prodynorphin gene transcription, suggesting that intracrine signals for growth regulation may be fashioned by an opioid gene.

The possibility that the prodynorphin gene may be involved in the orchestration of cardiogenesis may be of particular biological relevance. The attempt at rescuing the cardiac function in damaged myocardium is now an area of inquiry.35 Damaged skeletal muscle is able to regenerate because of the presence of satellite cells, which are undifferentiated myoblasts.36 In contrast, destruction of cardiac myocytes is associated with an irreversible loss of myocardium and replacement with scar tissue, because it lacks stem cells.36 Growing evidence indicates that stem cells obtained from skeletal muscle can be implanted into injured myocardium and are able to differentiate into cardiac muscle fibers,37 thereby providing a unique opportunity to repair damaged heart muscle. Strikingly, besides showing clear morphological evidence of a cardiac phenotype, the implanted cells exhibited long-term survival within the context of recipient myocardium.38 These findings are consistent with the hypothesis of milieu-influenced differentiation of the implanted stem cells into cardiac-like muscle cells. In previous investigations, we have shown that as a result of prodynorphin gene expression, dynorphin B is both synthesized and secreted from adult myocytes.10 16 17 18 In this study, we show that this opioid peptide is also secreted by an ES cell and may act in an autocrine fashion to elicit the appearance of a cardiac phenotype. Therefore, cardiac myocytes within the recipient myocardium and implanted stem cells might both generate a cardiogenic program involving the expression of an opioid gene and that of its related peptide product. In addition, dynorphin B itself has previously been shown to enhance prodynorphin gene expression in adult myocytes,18 19 suggesting that the local availability of dynorphin B may be enhanced by a paracrine crosstalk among myocytes and transplanted stem cells.

It is becoming evident that ES cells can be differentiated in vitro and used as a novel source of cells for transplantation.38 The results of the present study provide evidence that formation of a myocardial cell can be triggered in vitro by an opioid gene. Additional studies are needed to verify whether manipulation of the prodynorphin gene may prove effective in triggering cardiac differentiation in human stem cells implanted within an in vivo environment. Clarification of this issue must await more direct functional studies and may pave the way for developmental approaches to tissue engineering and myocardial regeneration.


*    Acknowledgments
 
This work was supported by grants from Ministero dell’ Università-Ricerca Scientifica e Tecnologica, Ministero della Sanità, Consiglio Nazionale delle Ricerche, and Regione Autonoma della Sardegna. The MF 20 antibody was provided by the Developmental Studies Hybridoma Bank, Iowa City, Iowa, and the phosphorothioate oligonucleotide and oligofectin were provided by Sequitur Inc, Natick, Mass. We acknowledge the fine technical assistance of Giuseppe DeLogu, Giuseppe Erre, Cinzia Sanna, Elisabetta Zinellu, and Emiliana Maninchedda.

Received May 3, 2000; accepted June 27, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Komuro I, Izumo S. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci U S A. 1993;90:8145–8149.[Abstract/Free Full Text]

2. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development. 1993;119:419–431.[Abstract]

3. Biben C, Harvey RP. Homeodomain factor Nkx-2.5 controls left/right asymmetric expression of bHLH gene eHand during murine heart development. Genes Dev. 1997;11:1357–1369.[Abstract/Free Full Text]

4. Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron BJ, Seidman CE, Seidman JG. Congenital heart disease caused by mutations in the transcription factor Nkx-2.5. Science. 1998;281:108–111.[Abstract/Free Full Text]

5. Benson DW, Silberbach GM, Kavanaugh-McHugh A, Cottrill C, Zhang Y, Riggs S, Smalls O, Johnson MC, Watson MS, Seidman JG, Seidman CE, Plowden J, Kugler JD. Mutations in the cardiac transcription factor Nkx-2.5 affect diverse cardiac developmental pathways. J Clin Invest. 1999;104:1567–1573.[Medline] [Order article via Infotrieve]

6. Wang GF, Nikovits W, Schleinitz M, Stockdale FE. A positive GATA element and a negative vitamin D receptor-like element control atrial chamber-specific expression of a slow myosin heavy-chain gene during cardiac morphogenesis. Mol Cell Biol. 1998;18:6023–6034.[Abstract/Free Full Text]

7. McBurney MW, Jones-Villeneuve EMW, Edwards MKS, Anderson PJ. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature. 1982;299:165–167.[Medline] [Order article via Infotrieve]

8. Skerjanc I, Petropoulos H, Ridgeway AG, Wilton S. Myocyte enhancer factor 2C and Nkx-2.5 up-regulate each other’s expression and initiate cardiomyogenesis in P19 cells. J Biol Chem. 1998;273:34904–34910.[Abstract/Free Full Text]

9. Grepin C, Robitaille L, Antakly T, Nemer M. Inhibition of transcription factor GATA-4 expression blocks in vitro cardiac muscle differentiation. Mol Cell Biol. 1995;15:4095–4102.[Abstract]

10. Ventura C, Guarnieri C, Vaona I, Campana G, Pintus G, Spampinato S. Dynorphin gene expression and release in the myocardial cell. J Biol Chem. 1994;269:5384–5386.[Abstract/Free Full Text]

11. Ventura C, Capogrossi MC, Spurgeon HA, Lakatta EG. {kappa}-Opioid peptide receptor stimulation increases cytosolic pH and myofilament responsiveness to Ca2+ in cardiac myocytes. Am J Physiol. 1991;261:H1671–H1674.[Abstract/Free Full Text]

12. Ventura C, Spurgeon HA, Lakatta EG, Guarnieri C, Capogrossi MC. {kappa} and {delta} Opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ Res. 1992;70:66–81.[Abstract/Free Full Text]

13. Zagon IS, Rhodes RE, McLaughlin PJ. Distribution of enkephalin immunoreactivity in germinative cells of developing rat cerebellum. Science. 1985;227:1049–1051.[Abstract/Free Full Text]

14. Maneckjee R, Minna JD. Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells. Proc Natl Acad Sci U S A. 1992;89:1169–1173.[Abstract/Free Full Text]

15. McLaughlin PJ. Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]enkephalin. Am J Physiol. 1996;271:R122–R129.[Abstract/Free Full Text]

16. Ventura C, Pintus G, Fiori MG, Bennardini F, Pinna G, Gaspa L. Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster, part I: regulation of prodynorphin gene expression by nuclear protein kinase C. J Biol Chem. 1997;272:6685–6692.[Abstract/Free Full Text]

17. Ventura C, Pintus G, Tadolini B. Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster, part II: role of intracellular calcium loading. J Biol Chem. 1997;272:6693–6698.[Abstract/Free Full Text]

18. Ventura C, Pintus G. Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster, part III: autocrine stimulation of prodynorphin gene expression by dynorphin B. J Biol Chem. 1997;272:6699–6705.[Abstract/Free Full Text]

19. Ventura C, Maioli M, Pintus G, Posadino AM, Tadolini B. Nuclear opioid receptors activate opioid peptide gene transcription in isolated myocardial nuclei. J Biol Chem. 1998;273:13383–13386.[Abstract/Free Full Text]

20. Pintus G, Tadolini B, Maioli M, Posadino AM, Gaspa L, Ventura C. Heparin down-regulates the phorbol ester-induced protein kinase C gene expression in human endothelial cells: enzyme-mediated autoregulation of protein kinase C-{alpha} and -{delta} genes. FEBS Lett. 1999;449:135–140.[Medline] [Order article via Infotrieve]

21. Bader D, Masaki T, Fischman DA. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J Cell Biol. 1982;95:763–770.[Abstract/Free Full Text]

22. Ladd AN, Yatskievych TA, Antin PB. Regulation of avian cardiac myogenesis by activin/TGFß and bone morphogenetic proteins. Dev Biol. 1998;204:407–419.[Medline] [Order article via Infotrieve]

23. Sparrow DB, Kotecha S, Towers N, Mohun T. Xenopus eHAND: a marker for the developing cardiovascular system of the embryo that is regulated by bone morphogenetic proteins. Mech Dev. 1998;71:151–163.[Medline] [Order article via Infotrieve]

24. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T. Smad5 and DPC4 are key molecules in mediating BMP-2–induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem. 1998;273:1872–1879.[Abstract/Free Full Text]

25. Shibuya H, Iwata H, Masuyama N, Gotoh Y, Yamaguchi K, Irie K, Matsumoto K, Nishida E, Ueno N. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J. 1998;17:1019–1028.[Medline] [Order article via Infotrieve]

26. Morely P, Whitfield JF. The differentiation inducer, dimethyl sulfoxide, transiently increases the intracellular calcium ion concentration in various cell types. J Cell Physiol. 1993;156:219–225.[Medline] [Order article via Infotrieve]

27. Ginestier-Verne C, Chateau MT, Bureau JP. Implication of tyrosine kinases and protein kinase C in dimethyl sulfoxide-induced apoptosis. Anal Cell Pathol. 1996;11:115–126.[Medline] [Order article via Infotrieve]

28. Mangoura D, Dawson G. Opioid peptides activate phospholipase D and protein kinase C-{epsilon} in chicken embryo neuron cultures. Proc Natl Acad Sci U S A. 1993;90:2915–2919.[Abstract/Free Full Text]

29. Ventura C, Pintus G, Vaona I, Bennardini F, Pinna G, Tadolini B. Phorbol ester regulation of opioid peptide gene expression in myocardial cells. J Biol Chem. 1995;270:30115–30120.[Abstract/Free Full Text]

30. Belcheva MM, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, Levy R, Young EC, Barg J, Coscia CJ. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gß{gamma} subunits. J Neurochem. 1998;70:635–645.[Medline] [Order article via Infotrieve]

31. Ventura C, Guarnieri C, Stefanelli C, Cirielli C, Lakatta EG, Capogrossi MC. Comparison between {alpha}-adrenergic and {kappa}-opioidergic mediated inositol(1,4,5)P3/inositol(1,3,4,5)P4 formation in adult cultured rat ventricular cardiomyocytes. Biochem Biophys Res Commun. 1991;179:972–978.[Medline] [Order article via Infotrieve]

32. Gu J, Ren K, Dubner R, Iadarola MJ. Cloning of a DNA binding protein that is a tyrosine kinase substrate and recognizes an upstream initiator-like sequence in the promoter of the prodynorphin gene. Brain Res Mol Brain Res. 1994;24:77–88.[Medline] [Order article via Infotrieve]

33. Bottger A, Spruce BA. Proenkephalin is a nuclear protein responsive to growth arrest and differentiation signals. J Cell Biol. 1995;130:1251–1262.[Abstract/Free Full Text]

34. Bakalkin GY, Ponomariev D, Sarkysian RA, Terenius L. Sequence similarity between opioid peptide precursors and DNA binding proteins. FEBS Lett. 1991;282:175–177.[Medline] [Order article via Infotrieve]

35. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697–705.[Medline] [Order article via Infotrieve]

36. Schultz E, McCormick KM. Skeletal muscle satellite cells. Rev Physiol Biochem Pharmacol. 1994;123:213–257.[Medline] [Order article via Infotrieve]

37. Chiu RC, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;60:12–18.[Abstract/Free Full Text]

38. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996;98:216–224.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. N. Re and J. L. Cook
The physiological basis of intracrine stem cell regulation
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H447 - H453.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Cadet, K. J. Mantione, W. Zhu, R. M. Kream, M. Sheehan, and G. B. Stefano
A Functionally Coupled {micro}3-Like Opiate Receptor/Nitric Oxide Regulatory Pathway in Human Multi-Lineage Progenitor Cells
J. Immunol., November 1, 2007; 179(9): 5839 - 5844.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
T. Oyama, T. Nagai, H. Wada, A. T. Naito, K. Matsuura, K. Iwanaga, T. Takahashi, M. Goto, Y. Mikami, N. Yasuda, et al.
Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo
J. Cell Biol., January 29, 2007; 176(3): 329 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Kim, A. L. Clark, A. Kiss, J. W. Hahn, R. Wesselschmidt, C. J. Coscia, and M. M. Belcheva
{micro}- and {kappa}-Opioids Induce the Differentiation of Embryonic Stem Cells to Neural Progenitors
J. Biol. Chem., November 3, 2006; 281(44): 33749 - 33760.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Ding, C.-j. Liu, Y. Huang, R. P. Hickey, J. Yu, W. Kong, and P. Lengyel
p204 Is Required for the Differentiation of P19 Murine Embryonal Carcinoma Cells to Beating Cardiac Myocytes: ITS EXPRESSION IS ACTIVATED BY THE CARDIAC GATA4, NKX2.5, AND TBX5 PROTEINS
J. Biol. Chem., May 26, 2006; 281(21): 14882 - 14892.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Fukuda and S. Yuasa
Stem Cells as a Source of Regenerative Cardiomyocytes
Circ. Res., April 28, 2006; 98(8): 1002 - 1013.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Hakuno, T. Takahashi, J. Lammerding, and R. T. Lee
Focal Adhesion Kinase Signaling Regulates Cardiogenesis of Embryonic Stem Cells
J. Biol. Chem., November 25, 2005; 280(47): 39534 - 39544.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
C. Ventura
CAM and Cell Fate Targeting: Molecular and Energetic Insights into Cell Growth and Differentiation
Evid. Based Complement. Altern. Med., September 1, 2005; 2(3): 277 - 283.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao
Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart
Cardiovasc Res, August 15, 2004; 63(3): 414 - 422.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Ventura, M. Maioli, Y. Asara, D. Santoni, I. Scarlata, S. Cantoni, and A. Perbellini
Butyric and Retinoic Mixed Ester of Hyaluronan: A NOVEL DIFFERENTIATING GLYCOCONJUGATE AFFORDING A HIGH THROUGHPUT OF CARDIOGENESIS IN EMBRYONIC STEM CELLS
J. Biol. Chem., May 28, 2004; 279(22): 23574 - 23579.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. C. Heng, H. K. Haider, E. K.-W. Sim, T. Cao, and S. C. Ng
Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro
Cardiovasc Res, April 1, 2004; 62(1): 34 - 42.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. J. Solloway and R. P. Harvey
Molecular pathways in myocardial development: a stem cell perspective
Cardiovasc Res, May 1, 2003; 58(2): 264 - 277.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Sachinidis, B. K. Fleischmann, E. Kolossov, M. Wartenberg, H. Sauer, and J. Hescheler
Cardiac specific differentiation of mouse embryonic stem cells
Cardiovasc Res, May 1, 2003; 58(2): 278 - 291.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Ventura, E. Zinellu, E. Maninchedda, M. Fadda, and M. Maioli
Protein Kinase C Signaling Transduces Endorphin-Primed Cardiogenesis in GTR1 Embryonic Stem Cells
Circ. Res., April 4, 2003; 92(6): 617 - 622.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Ventura, E. Zinellu, E. Maninchedda, and M. Maioli
Dynorphin B Is an Agonist of Nuclear Opioid Receptors Coupling Nuclear Protein Kinase C Activation to the Transcription of Cardiogenic Genes in GTR1 Embryonic Stem Cells
Circ. Res., April 4, 2003; 92(6): 623 - 629.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ventura, C.
Right arrow Articles by Maioli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ventura, C.
Right arrow Articles by Maioli, M.
Related Collections
Right arrow Gene expression
Right arrow Myogenesis
Right arrow Cardiac development